SCHEMBL3724433

SCHEMBL3724433

Cc1nc(NC(=O)OC(C)(C)C)sc1[C]=O

nearest known ligand 0.52

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
LCK P06239 12/20 0.52
PI4KB Q9UBF8 1/20 0.47
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2176751 0.87 LCK (0.52) LCKPI4KBCA1CA2
SCHEMBL2177852 0.83 LCK (0.48) LCKPI4KBCA1CA2
SCHEMBL13326568 0.81 LCK (0.56) LCKPI4KBCA1CA2
SCHEMBL30292658 0.80 LCK (0.46) LCKPI4KBCA1CA2
SCHEMBL2173294 0.79 LCK (0.54) LCKPI4KBCA1CA2
SCHEMBL150084 0.79 LCK (0.58) LCKPI4KBCA1CA2
SCHEMBL1796679 0.79 LCK (0.54) LCKPI4KBCA1CA2
SCHEMBL24735699 0.78 LCK (0.63) LCK
SCHEMBL538349 0.78 LCK (0.63) LCKPI4KBCA1CA2
SCHEMBL5402789 0.77 LCK (0.52) LCKPI4KBCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758564-A2 SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER Brystol-Myers Squibb Company (US) 2007-03-07 EP claimed
WO-2005094376-A2 SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER BRISTOL-MYERS SQUIBB COMPANY (US) 2005-10-13 WO claimed
WO-2010120388-A1 OLIGOMER-PROTEIN TYROSINE KINASE INHIBITOR CONJUGATES NEKTAR THERAPEUTICS (US) 2010-10-21 WO disclosed